Development asset linked to CRESCENT BIOPHARMA in public FDA and regional records.
biotech · Neonatal Infections · Locally Advanced / Metastatic Solid Tumors · CBIO
CRESCENT BIOPHARMA
CRESCENT BIOPHARMA, INC.
CRESCENT BIOPHARMA drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Waltham, USA HQ
57 Employees
Public company Type
CBIO · NYSE Ticker
Company details
- Status
- Public
- HQ
- Waltham, USA
- Employees
- 57
- Programs
- 3
- Drugs
- 5
- Patents
- 2
CRESCENT BIOPHARMA pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
CRESCENT BIOPHARMA drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Cell membrane.
- Target
- Cell membrane
- Mechanism
- Cell membrane inhibitor
-
Development asset linked to CRESCENT BIOPHARMA in public FDA and regional records.
-
folic acid
Various (V04)US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
- Target
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
- Mechanism
- Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor